Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients : Single center experience
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons..
Our aim was to evaluate the safety of transplanting kidneys from HCV-infected donors in HCV-uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor-specific antibodies and renal histology. Treatment with a direct-acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34% were female, 19% and 79% of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68-88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81%) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100% were HCV RNA-negative and achieved 12-week sustained virologic response. The estimated GFRs at end of treatment and 12-week posttreatment were 67 ± 21 mL/min/1.73 m2 and 67 ± 17 mL/min/1.73 m2 , respectively. Four recipients developed acute rejection. Kidney transplantation from HCV-infected donors to HCV-negative recipients should be considered in all eligible patients.
| Errataetall: |
CommentIn: Am J Transplant. 2019 Nov;19(11):2969-2970. - PMID 31448520 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 19(2019), 11 vom: 17. Nov., Seite 3046-3057 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Molnar, Miklos Z [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.09.2020 Date Revised 24.01.2023 published: Print-Electronic CommentIn: Am J Transplant. 2019 Nov;19(11):2969-2970. - PMID 31448520 Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.15530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299195104 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299195104 | ||
| 003 | DE-627 | ||
| 005 | 20231225095818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.15530 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM299195104 | ||
| 035 | |a (NLM)31306549 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Molnar, Miklos Z |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients |b Single center experience |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.09.2020 | ||
| 500 | |a Date Revised 24.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Transplant. 2019 Nov;19(11):2969-2970. - PMID 31448520 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a Our aim was to evaluate the safety of transplanting kidneys from HCV-infected donors in HCV-uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor-specific antibodies and renal histology. Treatment with a direct-acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34% were female, 19% and 79% of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68-88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81%) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100% were HCV RNA-negative and achieved 12-week sustained virologic response. The estimated GFRs at end of treatment and 12-week posttreatment were 67 ± 21 mL/min/1.73 m2 and 67 ± 17 mL/min/1.73 m2 , respectively. Four recipients developed acute rejection. Kidney transplantation from HCV-infected donors to HCV-negative recipients should be considered in all eligible patients | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical research/practice | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a infection and infectious agents - viral | |
| 650 | 4 | |a kidney (allograft) function/dysfunction | |
| 650 | 4 | |a kidney transplantation/nephrology | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Nair, Satheesh |e verfasserin |4 aut | |
| 700 | 1 | |a Cseprekal, Orsolya |e verfasserin |4 aut | |
| 700 | 1 | |a Yazawa, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Talwar, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Balaraman, Vasanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Podila, Pradeep S B |e verfasserin |4 aut | |
| 700 | 1 | |a Mas, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Maluf, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Helmick, Ryan A |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Nezakatgoo, Nosratollah |e verfasserin |4 aut | |
| 700 | 1 | |a Eymard, Corey |e verfasserin |4 aut | |
| 700 | 1 | |a Horton, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Rajanshu |e verfasserin |4 aut | |
| 700 | 1 | |a Jenkins, Ann Holbrook |e verfasserin |4 aut | |
| 700 | 1 | |a Handley, Charlotte R |e verfasserin |4 aut | |
| 700 | 1 | |a Snyder, Heather S |e verfasserin |4 aut | |
| 700 | 1 | |a Cummings, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Agbim, Uchenna A |e verfasserin |4 aut | |
| 700 | 1 | |a Maliakkal, Benedict |e verfasserin |4 aut | |
| 700 | 1 | |a Satapathy, Sanjaya K |e verfasserin |4 aut | |
| 700 | 1 | |a Eason, James D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 19(2019), 11 vom: 17. Nov., Seite 3046-3057 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:11 |g day:17 |g month:11 |g pages:3046-3057 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.15530 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 11 |b 17 |c 11 |h 3046-3057 | ||